Covered recipient · General Payments record
STEPHEN LIU
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$177,268.42
139 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $67,920.90 | 21 |
| Travel and Lodging | $66,444.04 | 46 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,031.90 | 25 |
| Food and Beverage | $2,871.58 | 47 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $59,252.28 | 30 |
| F. Hoffmann-La Roche AG | $30,651.20 | 20 |
| AstraZeneca Pharmaceuticals LP | $24,375.11 | 29 |
| AstraZeneca UK Limited | $19,033.61 | 14 |
| Celgene Corporation | $9,935.86 | 9 |
| Genentech USA, Inc. | $9,483.91 | 11 |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,082.69 | 3 |
| Lilly USA, LLC | $5,065.11 | 4 |
| Eli Lilly and Company | $4,347.84 | 7 |
| Boehringer Ingelheim International GmbH | $3,537.30 | 9 |
| Janssen Global Services, LLC | $2,480.00 | 2 |
| Genentech, Inc. | $23.51 | 1 |
Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
STEPHEN LIU
NPI 1184788432 · CMS profile ID 190501
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
LOS ANGELES, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1184788432?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- STEPHEN LIU, NPI 1184788432, CMS profile ID 190501. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184788432?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). STEPHEN LIU, NPI 1184788432, CMS profile ID 190501. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184788432?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- STEPHEN LIU, NPI 1184788432, CMS profile ID 190501, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184788432?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
139 matching records · $177,268.42 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–139 of 139.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corporation | $158.62 | 03/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695415061 | CMS |
| Merck Sharp & Dohme Corporation | $23.60 | 03/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695415063 | CMS |
| Merck Sharp & Dohme Corporation | $245.24 | 03/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695415065 | CMS |
| Merck Sharp & Dohme Corporation | $256.77 | 03/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695415067 | CMS |
| Merck Sharp & Dohme Corporation | $9,217.09 | 03/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695415229 | CMS |
| Genentech USA, Inc. | $3,640.00 | 03/18/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681338801 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,775.00 | 03/11/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685948763 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,775.00 | 03/10/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685806419 | CMS |
| AstraZeneca UK Limited | $7,000.00 | 03/06/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685798215 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $8,400.00 | 03/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697379591 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $502.79 | 03/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697379799 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $179.90 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697411695 | CMS |
| Celgene Corporation | $600.00 | 02/22/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672720527 | CMS |
| Genentech USA, Inc. | $198.87 | 02/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681149035 | CMS |
| Genentech USA, Inc. | $200.00 | 02/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681248695 | CMS |
| Genentech USA, Inc. | $447.87 | 02/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681264653 | CMS |
| Genentech USA, Inc. | $4,400.00 | 02/20/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681296235 | CMS |
| AstraZeneca UK Limited | $139.83 | 02/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685060665 | CMS |
| AstraZeneca Pharmaceuticals LP | $69.83 | 02/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685462601 | CMS |
| AstraZeneca UK Limited | $32.97 | 02/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685130485 | CMS |
| AstraZeneca UK Limited | $14.78 | 02/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685373087 | CMS |
| AstraZeneca UK Limited | $14.78 | 02/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685540455 | CMS |
| AstraZeneca UK Limited | $10,878.33 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685060279 | CMS |
| AstraZeneca UK Limited | $6.55 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685136385 | CMS |
| AstraZeneca UK Limited | $47.75 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685338655 | CMS |
| AstraZeneca UK Limited | $443.35 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685890819 | CMS |
| AstraZeneca UK Limited | $20.46 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685972397 | CMS |
| AstraZeneca UK Limited | $233.04 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685981731 | CMS |
| AstraZeneca Pharmaceuticals LP | $376.95 | 01/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685921505 | CMS |
| AstraZeneca Pharmaceuticals LP | $40.00 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685925475 | CMS |
| Merck Sharp & Dohme Corporation | $8,500.00 | 01/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695372269 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,720.00 | 01/07/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685124051 | CMS |
| Merck Sharp & Dohme Corporation | $19.00 | 01/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695372245 | CMS |
| Merck Sharp & Dohme Corporation | $23.00 | 01/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695372249 | CMS |
| Merck Sharp & Dohme Corporation | $19.00 | 01/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695372241 | CMS |
| Merck Sharp & Dohme Corporation | $345.00 | 01/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695372253 | CMS |
| Merck Sharp & Dohme Corporation | $5,339.00 | 01/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695372261 | CMS |
| Merck Sharp & Dohme Corporation | $540.00 | 01/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695372265 | CMS |
| Merck Sharp & Dohme Corporation | $44.00 | 01/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695372257 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $8,784.06 | 6 |
| PY2025 | Principal investigator | $891,018.79 | 178 |
| PY2024 | Recipient | $4,600.00 | 2 |
| PY2024 | Principal investigator | $1,653,888.85 | 126 |
| PY2023 | Principal investigator | $1,104,134.85 | 45 |
| PY2022 | Recipient | $1,967.66 | 1 |
| PY2022 | Principal investigator | $793,468.72 | 28 |
| PY2021 | Recipient | $4,288.84 | 6 |
| PY2021 | Principal investigator | $978,939.81 | 53 |
| PY2020 | Recipient | $12,864.69 | 21 |
| PY2020 | Principal investigator | $886,024.56 | 67 |
| PY2019 | Recipient | $3,323.20 | 1 |
| PY2019 | Principal investigator | $936,390.66 | 74 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
184 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202532538 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $6,010.67 | 12/31/2025 | Non-covered Recipient Entity Georgetown University | KEYMAKER-U01 Substudy 01A# A Phase 1,2, Umbrella Study With Rolling Arms of Investigational Agents, With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer NSCLC | No dispute reported | 06/30/2026 | 1232924760 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $48.62 | 12/31/2025 | Non-covered Recipient Entity Georgetown University | KEYMAKER U01Substudy 2# A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Na ve Patients with PD-L1 Positive Advanced Non-Small Cell Lung Cancer NSCLC | No dispute reported | 06/30/2026 | 1232925223 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $161,551.60 | 12/31/2025 | Non-covered Recipient Entity Georgetown University | KEYMAKER-U01 Master Study# A Phase 1,2, Umbrella Study with Rolling Arms of Investigational Agents, Pembrolizumab, and Chemotherapy, Alone or in Combination, in Participants with Non-small Cell Lung Cancer NSCLC | No dispute reported | 06/30/2026 | 1232928457 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $15,450.74 | 12/31/2025 | Non-covered Recipient Entity Georgetown University Medical Center | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r | No dispute reported | 06/30/2026 | 1232939895 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610120 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610124 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610128 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610132 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610136 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610144 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610148 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610153 |
| Principal investigator 1 | Genentech, Inc. | $16.50 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610157 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610161 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610164 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610169 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610174 |
| Principal investigator 1 | Genentech, Inc. | $2,467.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610178 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610184 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610189 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610193 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610197 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610201 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610205 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610208 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610212 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610216 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610220 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610224 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610228 |
| Principal investigator 1 | Genentech, Inc. | $1,634.80 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610233 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 12/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610239 |
| Principal investigator 1 | Incyte Corporation | $18,385.00 | 12/24/2025 | Covered Recipient Teaching Hospital Georgetown University Hospital | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240474106 |
| Principal investigator 1 | ABBVIE INC. | $365.30 | 12/19/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202531384 |
| Principal investigator 1 | ABBVIE INC. | $365.30 | 12/19/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202531386 |
| Principal investigator 1 | ABBVIE INC. | $2,347.80 | 12/19/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202531410 |
| Principal investigator 1 | ABBVIE INC. | $365.30 | 12/19/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202531412 |
| Principal investigator 1 | ABBVIE INC. | $344.50 | 12/19/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202531414 |
| Principal investigator 1 | ABBVIE INC. | $975.27 | 12/19/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202531416 |
| Principal investigator 1 | ABBVIE INC. | $1,006.94 | 12/19/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202531418 |
| Recipient | F. Hoffmann-La Roche AG | $781.10 | 12/11/2025 | Covered Recipient Physician | 1LM SCLC Tecentriq Lurbinectedin | No dispute reported | 06/30/2026 | 1211539043 |
| Recipient | F. Hoffmann-La Roche AG | $1,143.94 | 12/11/2025 | Covered Recipient Physician | 1LM SCLC Tecentriq Lurbinectedin | No dispute reported | 06/30/2026 | 1211539050 |
| Principal investigator 1 | Genentech, Inc. | $650.00 | 12/02/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610116 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 12/02/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610140 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 11/27/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202525768 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 11/27/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202525770 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 11/27/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202525772 |
| Recipient | F. Hoffmann-La Roche AG | $3,691.13 | 11/27/2025 | Covered Recipient Physician | 1LM SCLC Tecentriq Lurbinectedin | No dispute reported | 06/30/2026 | 1211539039 |
| Principal investigator 1 | Genentech, Inc. | $1,014.00 | 11/20/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS | Neoadjuvant NSCLC | No dispute reported | 06/30/2026 | 1211610398 |
| Principal investigator 1 | Genentech, Inc. | $5,925.00 | 11/05/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211610777 |
| Principal investigator 1 | Partner Therapeutics, Inc. | $1,164.80 | 11/05/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | No dispute reported | 06/30/2026 | 1215516757 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 10/30/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202519657 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 10/30/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202519659 |
| Principal investigator 1 | ABBVIE INC. | $1,300.00 | 10/30/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202519661 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 10/30/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202519663 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 10/30/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202519665 |
| Principal investigator 1 | ABBVIE INC. | $1,690.00 | 10/30/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202519667 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 10/27/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202518557 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 10/27/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202518559 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 10/27/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202518563 |
| Recipient | Novartis Pharma AG | $1,080.75 | 10/18/2025 | Covered Recipient Physician | CAAA601A42101 | No dispute reported | 06/30/2026 | 1248109605 |
| Principal investigator 1 | Incyte Corporation | $37.53 | 10/08/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240537178 |
| Principal investigator 1 | Genentech, Inc. | $3,387.80 | 10/07/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211610773 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 09/29/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202512588 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 09/29/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202512590 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 09/29/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202512592 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 09/29/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202512608 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 09/29/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202512626 |
| Principal investigator 1 | ABBVIE INC. | $365.30 | 09/25/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202512212 |
| Principal investigator 1 | ABBVIE INC. | $365.30 | 09/25/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202512214 |
| Principal investigator 1 | ABBVIE INC. | $975.27 | 09/25/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202512226 |
| Principal investigator 1 | ABBVIE INC. | $1,006.94 | 09/25/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202512228 |
| Principal investigator 1 | ABBVIE INC. | $2,347.80 | 09/25/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202512252 |
| Principal investigator 1 | ABBVIE INC. | $365.30 | 09/25/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202512254 |
| Principal investigator 1 | ABBVIE INC. | $344.50 | 09/25/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202512256 |
| Principal investigator 1 | Genentech, Inc. | $6,172.00 | 09/24/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610104 |
| Principal investigator 1 | Genentech, Inc. | $18,516.00 | 09/23/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610099 |
| Principal investigator 1 | Genentech, Inc. | $9,904.00 | 09/23/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610108 |
| Principal investigator 1 | Genentech, Inc. | $6,890.00 | 09/23/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC | No dispute reported | 06/30/2026 | 1211610357 |
| Principal investigator 1 | Genentech, Inc. | $2,400.00 | 09/23/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC | No dispute reported | 06/30/2026 | 1211610361 |
| Principal investigator 1 | Genentech, Inc. | $2,322.00 | 09/22/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610095 |
| Principal investigator 1 | Genentech, Inc. | $1,248.00 | 09/22/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610112 |
| Recipient | F. Hoffmann-La Roche AG | $1,641.54 | 09/17/2025 | Covered Recipient Physician | 1LM SCLC Tecentriq Lurbinectedin | No dispute reported | 06/30/2026 | 1211539047 |
| Principal investigator 1 | Genentech, Inc. | $16,500.00 | 09/17/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS | Neoadjuvant NSCLC | No dispute reported | 06/30/2026 | 1211610393 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 09/01/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202506669 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 09/01/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202506671 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 09/01/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202506689 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 08/04/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202500930 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 08/04/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202500932 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $54,159.58 | 07/30/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185545093 |
| Principal investigator 1 | ABBVIE INC. | $3,250.00 | 07/09/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202497532 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 07/09/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202497534 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 07/09/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202497536 |
| Principal investigator 1 | ABBVIE INC. | $2,347.80 | 07/04/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202496916 |
| Principal investigator 1 | ABBVIE INC. | $344.50 | 07/04/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202496918 |
| Principal investigator 1 | ABBVIE INC. | $365.30 | 07/04/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202496920 |
| Principal investigator 1 | ABBVIE INC. | $1,006.94 | 07/04/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202496922 |
| Principal investigator 1 | ABBVIE INC. | $365.30 | 07/04/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202496924 |
| Principal investigator 1 | ABBVIE INC. | $975.27 | 07/04/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202496928 |
| Principal investigator 1 | ABBVIE INC. | $365.30 | 07/04/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202496930 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610653 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610657 |
| Principal investigator 1 | Genentech, Inc. | $2,467.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610662 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610665 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610671 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610676 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610680 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610684 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610689 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610693 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610696 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610701 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610705 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610709 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610714 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610718 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610722 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610726 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610730 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610734 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610738 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610742 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610746 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610748 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610753 |
| Principal investigator 1 | Genentech, Inc. | $832.20 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610757 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610760 |
| Principal investigator 1 | Genentech, Inc. | $439.00 | 07/03/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY PRESIDENT + DIRECTORS OF GEORGETOWN COLLEGE FOR GEORGETOWN UNIV | STARTRK 2 RXDX 101 02 | No dispute reported | 06/30/2026 | 1211610764 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 06/26/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202492931 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 06/26/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202493095 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 06/26/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202493097 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 06/26/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202493105 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 06/26/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202493107 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 06/26/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202493109 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 06/26/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202493111 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $16,365.00 | 06/23/2025 | Non-covered Recipient Entity Georgetown University Medical Center | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r | No dispute reported | 06/30/2026 | 1232937050 |
| Principal investigator 1 | Incyte Corporation | $11,524.00 | 06/05/2025 | Covered Recipient Teaching Hospital Georgetown University Hospital | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240474094 |
| Principal investigator 1 | Incyte Corporation | $11,680.00 | 06/05/2025 | Covered Recipient Teaching Hospital Georgetown University Hospital | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240474098 |
| Principal investigator 1 | Incyte Corporation | $600.00 | 06/05/2025 | Covered Recipient Teaching Hospital Georgetown University Hospital | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240474102 |
| Principal investigator 1 | ABBVIE INC. | $12,990.03 | 06/02/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202487165 |
| Principal investigator 1 | ABBVIE INC. | $1,033.50 | 06/02/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202487257 |
| Principal investigator 1 | ABBVIE INC. | $1,095.90 | 06/02/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202487259 |
| Principal investigator 1 | ABBVIE INC. | $1,095.90 | 06/02/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202487261 |
| Principal investigator 1 | ABBVIE INC. | $1,095.90 | 06/02/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202487267 |
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 05/28/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202486403 |
| Principal investigator 1 | ABBVIE INC. | $3,575.00 | 05/28/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202486405 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 05/28/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202486407 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 05/28/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202486409 |
| Principal investigator 1 | Incyte Corporation | $800.00 | 05/28/2025 | Covered Recipient Teaching Hospital Georgetown University Hospital | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240474086 |
| Principal investigator 1 | Incyte Corporation | $12,668.00 | 05/22/2025 | Covered Recipient Teaching Hospital Georgetown University Hospital | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240474090 |
| Recipient | Novartis Pharma AG | $445.60 | 05/13/2025 | Covered Recipient Physician | CAAA601A42101 | No dispute reported | 06/30/2026 | 1248109607 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 04/28/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202479707 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 04/28/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202479711 |
| Principal investigator 1 | Incyte Corporation | $11,791.00 | 04/17/2025 | Covered Recipient Teaching Hospital Georgetown University Hospital | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240474083 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $16,432.00 | 04/04/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | BLU667 1101 ARROW ongoing | No dispute reported | 06/30/2026 | 1211610091 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 03/26/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202466417 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 03/26/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202466422 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $47,412.00 | 03/26/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | BLU667 1101 ARROW ongoing | No dispute reported | 06/30/2026 | 1211610082 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $832.00 | 03/21/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | BLU667 1101 ARROW ongoing | No dispute reported | 06/30/2026 | 1211610066 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $16,525.08 | 03/21/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | BLU667 1101 ARROW ongoing | No dispute reported | 06/30/2026 | 1211610078 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $20,280.78 | 03/21/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | BLU667 1101 ARROW ongoing | No dispute reported | 06/30/2026 | 1211610086 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 03/12/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202462876 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 03/12/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202462879 |
| Principal investigator 1 | Partner Therapeutics, Inc. | $10,913.60 | 03/12/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | No dispute reported | 06/30/2026 | 1215516403 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,760.00 | 02/28/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | BLU667 1101 ARROW ongoing | No dispute reported | 06/30/2026 | 1211610074 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 02/27/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202454892 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 02/27/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202454896 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 02/27/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202454927 |
| Principal investigator 1 | ABBVIE INC. | $4,463.00 | 02/27/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202454932 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 02/27/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202454936 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $30,500.00 | 02/21/2025 | Non-covered Recipient Entity Medstar Research Institute | A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | No dispute reported | 06/30/2026 | 1236530951 |
| Principal investigator 1 | Genentech, Inc. | $6,900.00 | 02/19/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY GEORGETOWN UNIV CLINICAL TRIALS | 1LM SCLC Tecentriq Lurbinectedin | No dispute reported | 06/30/2026 | 1211610390 |
| Principal investigator 1 | ABBVIE INC. | $1,300.00 | 02/13/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202451697 |
| Principal investigator 1 | ABBVIE INC. | $1,690.00 | 02/13/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202451701 |
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 02/13/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | Study to Evaluate Adverse Events Change in Disease Activity and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab Cisplatin or Carboplatin in Adult Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202451709 |
| Principal investigator 1 | Incyte Corporation | $15,075.00 | 02/13/2025 | Covered Recipient Teaching Hospital Georgetown University Hospital | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240474110 |
| Principal investigator 1 | Incyte Corporation | $2,734.00 | 02/06/2025 | Covered Recipient Teaching Hospital Georgetown University Hospital | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240474114 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $12,300.03 | 02/05/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | BLU667 1101 ARROW ongoing | No dispute reported | 06/30/2026 | 1211610070 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 01/29/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202442046 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 01/29/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202442461 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 01/29/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202442465 |
| Principal investigator 1 | ABBVIE INC. | $1,543.00 | 01/29/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination with Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202442469 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $133,495.00 | 01/29/2025 | Non-covered Recipient Entity GEORGETOWN UNIVERSITY | EIH study with DLL3 CD3 4 1BBL TCE in SCLC and NEC | No dispute reported | 06/30/2026 | 1211610336 |